Search
C4 Therapeutics Inc
CCCCAdd to Watchlist
4.300USD
-0.040-0.92%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
447.36MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.92%
5 Days
+0.94%
1 Month
+3.12%
6 Months
+122.80%
Year to Date
+125.13%
1 Year
+190.54%
Key Figures
4.370Open
4.430High
2.62MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.52%Turnover Ratio
4.340Prev. Close
4.150Low
8.13MTurnover
LossP/E Static
1.91P/B
0.00%Div Yield TTM
-32.02%ROA
3.96552wk High
0.58Volume Ratio
-105.32MNet Profit
104.04MShares
-1.0943EPS TTM
2.84Beta
-48.35%ROE
1.21052wk Low
6.45%Amplitude
100.00%Gross Margin
447.36MMarket Cap
0.65Reward/Risk
6.29%Risk Rate
TradingKey Stock Score of C4 Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
C4 Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 122 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.33.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
C4 Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
C4 Therapeutics Inc Highlights
StrengthsRisks
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 73.19% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 35.95M.
Undervalued
The company’s latest PE is -3.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 76.03M shares, decreasing 10.35% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 118.91K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.333
Target Price
+207.22%
Upside Space
C4 Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
C4 Therapeutics Inc Info
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Ticker SymbolCCCC
CompanyC4 Therapeutics Inc
CEOHirsch (Andrew J)
Websitehttps://c4therapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of C4 Therapeutics Inc (CCCC)?
The current price of C4 Therapeutics Inc (CCCC) is 4.30.
What is the symbol of C4 Therapeutics Inc?
The ticker symbol of C4 Therapeutics Inc is CCCC.
What is the 52-week high of C4 Therapeutics Inc?
The 52-week high of C4 Therapeutics Inc is 3.96.
What is the 52-week low of C4 Therapeutics Inc?
The 52-week low of C4 Therapeutics Inc is 1.21.
What is the market capitalization of C4 Therapeutics Inc?
The market capitalization of C4 Therapeutics Inc is 447.36M.
Is C4 Therapeutics Inc (CCCC) currently rated as Buy, Hold, or Sell?
According to analysts, C4 Therapeutics Inc (CCCC) has an overall rating of Buy, with a price target of 13.33.
What is the Earnings Per Share (EPS TTM) of C4 Therapeutics Inc (CCCC)?
The Earnings Per Share (EPS TTM) of C4 Therapeutics Inc (CCCC) is -1.27.